請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45922
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建仁(Chien-Jen Chen) | |
dc.contributor.author | Mei-Hsuan Lee | en |
dc.contributor.author | 李美璇 | zh_TW |
dc.date.accessioned | 2021-06-15T04:48:56Z | - |
dc.date.available | 2011-07-28 | |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-03 | |
dc.identifier.citation | 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-brone non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44. 3. Chen DS, Kuo GC, Sung JL, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience.[see comment]. J Infect Dis 1990;162:817-22. 4. Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946-52. 5. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35. 6. Hepatitis C: global prevalence; 1999. 7. Lavanchy D, Purcell R, Hollinger FB, et al. Global surveillance and control of hepatitis C. J Viral Hepat 1999;6:35-47. 8. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Inf Dis 2002;2:293-302. 9. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.[see comment]. N Engl J Med 1999;341:556-62. 10. Chowdhury A, Santra A, Chaudhuri S, et al. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003;37:802-9. 11. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: Prevalence and clinical spectrum. Scand J Gastroenterol 2003;38:864-70. 12. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997;25:1490-6. 13. Gogos CA, Fouka KP, Nikiforidis G, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003;18:551-7. 14. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11. 15. Habib M, Mohamed MK, Abdel-Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: Risk factors for seropositivity. Hepatology 2001;33:248-53. 16. Okayama A, Stuver SO, Tabor E, et al. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat 2002;9:43-51. 17. Perez CM, Suarez E, Torres EA, Roman K, Colon V. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. Int J Epidemiol 2005;34:593-9. 18. Riestra S, Fernandez E, Leiva P, Garcia S, Ocio G, Rodrigo L. Prevalence of hepatitis C virus infection in the general population of northern Spain. Eur J Gastroenterol Hepatol 2001;13:477-81. 19. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:290-6. 20. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or type B. N Engl J Med 1975;292:767-70. 21. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. 22. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155:645-53. 23. Shin HR, Kim JY, Kim JI, et al. Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. Br J Cancer 2002;87:314-8. 24. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91:42-6. 25. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67. 26. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29. 27. Akhtar S, Moatter T. Multilevel modeling of intra-household spread of hepatitis C virus infection, Karachi, Pakistan. Am J Trop Med Hyg 2007;76:446-9. 28. McMahon JM, Pouget ER, Tortu S. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: A multilevel dyadic analysis. J Infect Dis 2007;195:1572-81. 29. Hutchinson SJ, Goldberg DJ, King M, et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 2004;53:593-8. 30. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33. 31. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63. 32. Suruki R, Hayashi K, Kusumoto K, et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 2006;119:192-5. 33. Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004;112:1075-80. 34. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection - Host, viral, and environmental factors. JAMA 2000;284:450-6. 35. Tong MJ, Elfarra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6. 36. Uto H, Stuver SO, Hayashi K, et al. Increased Rate of Death Related to Presence of Viremia Among Hepatitis C Virus Antibody-Positive Subjects in a Community-Based Cohort Study. Hepatology 2009;50:393-9. 37. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005;43:590-8. 38. Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. International Hepatology Communications 1996;5:62-73. 39. Lauer GM, Walker BD. Hepatitis C virus infection.[see comment]. N Engl J Med 2001;345:41-52. 40. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127:S35-S50. 41. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127-34. 42. Dusheiko G, Schmilovitzweiss H, Brown D, et al. Hepatitis C virus genotypes an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8. 43. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepat 1999;6:435-43. 44. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis c virus infection in Italy. J Med Virol 2005;76:327-32. 45. Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K. Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. J Med Virol 2005;76:185-93. 46. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16. 47. Chang HC, Yu MW, Lu CF, Chiu YH, Chen CJ. Risk factors associated with hepatitis C virus infection in Taiwanese government employees. Epidemiol Infect 2001;126:291-9. 48. Wang CS, Chang TT, Chou P. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J Clin Epidemiol 1998;51:733-8. 49. McMahon BJ, Hennessy TW, Christensen C, et al. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004;39:325-32. 50. Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001;65:30-4. 51. Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health 2000;21:171-92. 52. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007;5:921-31. 53. Armstrong D, Barnett E, Casper M, Wing S. Community occupational structure, medical and economic resources, and coronary mortality among US blacks and whites, 1980-1988. Ann Epidemiol 1998;8:184-91. 54. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology 2009;136:496-504. 55. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659-66. 56. Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 2006;60:290-7. 57. Merlo J, Chaix B, Yang M, Lynch J, Rastam L. A brief conceptual tutorial on multilevel analysis in social epidemiology: interpreting neighbourhood differences and the effect of neighbourhood characteristics on individual health. J Epidemiol Community Health 2005;59:1022-8. 58. Merlo J, Yang M, Chaix B, Lynch J, Rastam L. A brief conceptual tutorial on multilevel analysis in social epidemiology: investigating contextual phenomena in different groups of people. J Epidemiol Community Health 2005;59:729-36. 59. Larsen K, Merlo J. Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression.[see comment]. Am J Epidemiol 2005;161:81-8. 60. Browne W. In: MCMC estimation in MLwiN version 20 London, UK: Centre for Multilevel Modelling, Institute of Education, University of London, 2003:297. 61. Rasbash J, Steele F, Browne W. In: A user's guide to MLwiN, version 20 Documentation Version 21e London: Centre for Multilevel Modelling Institute of Education University of London, 2003. 62. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999;31:54-60. 63. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection - A systematic review. JAMA 2007;297:724-32. 64. Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in northeast Italy. J Med Virol 2002;68:352-6. 65. Mujeeb SA, Shahab S, Hyder AA. Geographical display of health information: study of hepatitis C infection in Karachi, Pakistan.[erratum appears in Public Health 2001 Jan;115(1):82]. Public Health 2000;114:413-5. 66. Piantadosi S, Byar DP, Green SB. The ecological fallacy. Am J Epidemiol 1988;127:893-904. 67. Tovo PA, Pembrey L, Newell ML, et al. A significant sex - but not elective cesarean section - Effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005;192:1872-9. 68. Chen KT, Chen CJ, Fagot-Campagna A, Narayan KMV. Tobacco, betel quid, alcohol, and illicit drug use among 13-to 35-year-olds in I-Lan, rural Taiwan: Prevalence and risk factors. Am J Public Health 2001;91:1130-4. 69. Chiang SC, Chen CY, Chang YY, Sun HJ, Chen WJ. Prevalence of heroin and methamphetamine male users in the northern Taiwan, 1999-2002: capture-recapture estimates. BMC Public Health 2007;7. 70. Chou P, Liou MY, Lai MY, Hsiao ML, Chang HJ. Time trend of substance use among adolescent students in Taiwan, 1991-1996. J Formos Med Assoc 1999;98:827-31. 71. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S4. 72. El-Serag HB, Rudolph L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. 73. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009;49:1335-74. 74. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. 75. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93. 76. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51. 77. Poynard T, Yuen M-F, Ratziu V, Lai CL. Viral hepatitis C.[see comment]. Lancet 2003;362:2095-100. 78. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350-6. 79. Silini E, Bottelli R, Asti M, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case-control study. Gastroenterology 1996;111:199-205. 80. Sun CA, Farzadegan H, You SL, et al. Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: A population-based case-control study in Taiwan. Cancer Epidemiol Biomarkers Prev 1996;5:173-8. 81. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: Possible role of type 1b (II) infection. J Natl Cancer Inst 1996;88:742-6. 82. Yates SC, Hafez M, Beld M, et al. Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: Association with hepatitis C virus (HCV) infection but not with HCV RNA level. Am J Trop Med Hyg 1999;60:714-20. 83. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70. 84. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. 85. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30. 86. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5. 87. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81. 88. Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 1999;31:593-7. 89. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48. 90. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32. 91. Wu CH, Lee MF, Kuo HS. Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterol Hepatol 1997;12:625-8. 92. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9. 93. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009;360:1902-6. 94. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98, vi. 95. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167:743-50. 96. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11. 97. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11. 98. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13. 99. Ali A, Zein NN. Hepatitis C infection: A systemic disease with extrahepatic manifestations. Cleve Clin J Med 2005;72:1005-+. 100. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences. Hepatology 2006;44:15-22. 101. Fwu CW, Chien YC, Nelson KE, et al. Mortality after chronic hepatitis B virus infection: a linkage study involving 2 million parous women from Taiwan. J Infect Dis 2010;201:1016-23. 102. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008;47:1128-35. 103. Lehman EM, Wilson ML. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J Viral Hepat 2009;16:650-8. 104. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938-45. 105. McDonald SA, Hutchinson SJ, Bird SM, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009;18:271-83. 106. Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007;56:1098-104. 107. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009;16:644-9. 108. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000;181:35-41. 109. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-9. 110. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus lnfection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007;166:196-203. 111. Arase Y, Suzuki F, Suzuki Y, et al. Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C. Hepatology 2009;49:739-44. 112. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8. 113. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007;167:1271-6. 114. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006;17:1168-74. 115. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70. 116. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 1999;106:347-54. 117. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk Factors for End-Stage Renal Disease 25-Year Follow-up. Arch Intern Med 2009;169:342-50. 118. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack - A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke - Co-sponsored by the Council on Cardiovascular Radiology and Intervention - The American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617. 119. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease: Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-20. 120. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76. 121. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. 122. Nieto FJ. Infections and atherosclerosis: New clues from an old hypothesis? Am J Epidemiol 1998;148:937-48. 123. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA 2003;289:1245-6. 124. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-5. 125. Ishizaka Y, Ishizaka N, Takahashi E, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circulation J 2003;67:26-30. 126. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22. 127. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-21. 128. Barba C, Cavalli-Sforza T, Cutter J, et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63. 129. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-421. 130. Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Trans 2002;2:443-7. 131. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999;67:272-5. 132. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006;43:E53-E6. 133. Volzke H, Schwahn C, Wolff B, et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004;174:99-103. 134. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis - Prospective results from a large population study. Circulation 2001;103:1064-70. 135. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002;33:2581-6. 136. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8. 137. Hansson GK. Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95. 138. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-7. 139. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Inf Dis 2005;5:227-36. 140. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610. 141. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007. 142. Marchioni E, Ceroni M, Erbetta A, et al. Severe acute cerebrovascular disease revealing hepatitis C virus infection: effectiveness of alpha-interferon. J Neurol 2002;249:1111-3. 143. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-9. 144. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003;10:81-6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45922 | - |
dc.description.abstract | 本論文以四個子研究探討C型肝炎病毒感染在台灣地區的流行病學特性。第一部分評估C型肝炎病毒在社區的血清盛行率及地理分布差異,並以多層次分析模式探討地區特性及個人危險因子與C型肝炎病毒感染的相關。第二部份以追蹤研究方式,評估血清標記,包含血清C型肝炎病毒核糖核酸濃度(HCV RNA levels)、C型肝炎病毒基因型及丙胺酸轉胺酶(alanine aminotransferase, ALT)對C型肝炎病毒血清陽性者發生肝癌的預測性。第三部份除估計C型肝炎病毒感染對於肝硬化、肝癌死亡的影響,並系統性估計C型肝炎病毒對於肝外疾病(extrahepatic diseases)死亡的危險性。第四部份分析C型肝炎病毒血清病毒核糖核酸濃度對於腦血管疾病死亡風險是否存在劑量效應,以確立病毒感染與此肝外疾病的關聯性。
研究一、C型肝炎病毒血清盛行率的地理分布差異與決定因子 背景:居住在鄰近或相同地區的人共享環境,因此感染病毒的機會理當相似。C型肝炎病毒感染的個人危險因子常被探討,但環境特性卻鮮少被提及。本研究利用多層次分析方法,在考慮個人危險因子的條件下,評估地區特性:C型肝炎病毒核糖核酸血清陽性率及醫療資源,對於個人感染C型肝炎病毒風險之影響。方法:研究選取台灣地區7個鄉鎮共155個村里的居民共23,820人。研究個案進入研究時測量血清中抗C型肝炎病毒抗體,若此抗體為陽性則進一步檢驗血清中的C型肝炎病毒核糖核酸與C型肝炎病毒基因型。結果:C型肝炎病毒血清盛行率為5.5%,其中血清C型肝炎病毒抗體為陽性者中,有68.1%為C型肝炎病毒核糖核酸陽性。在社區中,以感染C型肝炎病毒第一基因型者為盛行。個人危險因子如年齡老化、女性、低教育程度及輸血經驗皆和病毒感染風險有關。透過多層次模式分析,在控制個人危險因子的條件之下,地區特性如C型肝炎病毒核糖核酸血清陽性率及醫療資源,對於病毒感染有重要的影響。C型肝炎病毒核糖核酸血清陽性率高的地區相對於陽性率低的地區,校正後的風險對比值為3.74 (95%信賴區間:2.50-5.19);醫療資源有限相對於有適當醫療資源的地區校正後的風險對比值為1.90 (95%信賴區間:1.34-2.69)。結論:地區的特性和C型肝炎病毒感染的盛行有關聯。本研究結果顯示在社區中若要有效控制病毒的感染,必須有效分配醫療資源並且找出C型肝炎病毒抗體陽性且C型肝炎病毒核糖核酸血清陽性(即慢性感染)的個案,並且予以有效的治療及臨床處置。 研究二、C型肝炎病毒感染之血清標記對肝癌發生之預測性 背景:針對和C型肝炎病毒感染有關的肝癌發生,找出長期的預測因子能夠提供早期臨床處置的依據。本研究評估血清中的C型肝炎病毒核糖核酸濃度、C型肝炎病毒基因型別及丙胺酸轉胺酶對於C型肝炎病毒感染者未來發生肝癌之預測性。方法:自1991至2006年針對925名C型肝炎病毒抗體陽性,且年齡介於30至65歲的成年人作追蹤。研究個案血清中之C型肝炎病毒核糖核酸濃度、C型肝炎病毒基因型別及丙胺酸轉胺酶在納入研究時即已測量,研究世代之新發肝癌乃透過定期的健康檢查、癌症登記檔及死亡檔的連結做確立。結果:截至研究結束追蹤8,476人年,其中共有55名肝癌新發個案。研究個案血清中之C型肝炎病毒核糖核酸陰性、或血清中C型肝炎病毒量低,或血清中C型肝炎病毒量高之肝癌發生累積風險(cumulative risk)分別為1.1%,6.4%及14.7%;且三組之間達到統計上的顯著差異。血清中丙胺酸轉胺酶濃度對肝癌的累積風險,丙胺酸轉胺酶濃度持續等於或低於15 U/L者為1.7%,曾經高於15 U/L但未高於45 U/L者為4.2%;而追蹤過程中曾經高於45 U/L者為13.8%。而感染C型肝炎病毒第一基因型者相對於感染非第一基因型者有較高肝癌發生累積風險,分別為12.6%及4.5%。結論:血清中的C型肝炎病毒濃度高、感染C型肝炎病毒第一基因型及高濃度丙胺酸轉胺酶能預測C肝感染者之肝癌發生。 研究三、C型肝炎病毒對肝內及肝外疾病死亡率之風險 背景:C型肝炎病毒感染除了會導致肝臟疾病,亦可能增加罹患肝外疾病的風險。然而,C型肝炎病毒感染與肝內及肝外疾病死因的關聯卻鮮少被評估。方法:研究自1991年起追蹤台灣七鄉鎮社區30-65歲的成人至2008年底,研究個案為B型肝炎病毒表面抗原陰性者。研究個案之死亡資料以連結死亡登記檔取得,並依照國際疾病分類碼第九版(ICD-9)做死因之分類。結果:本研究共有19,636名B型肝炎病毒表面抗原陰性者納入分析,其中1,095人為C型肝炎病毒抗體陽性,另18,541人則為C型肝炎病毒抗體陰性。在C型肝炎病毒抗體陽性者中,有69.4%病毒核糖核酸陽性,表示病毒仍在持續複製,為慢性感染者。經過平均16.2年的追蹤,本研究世代共有2,394人死亡,死亡率為每十萬人年753.4人。將研究個案分成C型肝炎病毒抗體陰性、C型肝炎病毒抗體陽性但核醣核酸陰性、及C型肝炎病毒抗體陽性且核醣核酸陽性三組,全死因死亡率(每十萬人年)分別為708.8,741.0及1879.8;而肝臟相關疾病死亡率(每十萬人年)則分別為37.2,82.3,678.3。針對全死因、肝臟疾病死亡及肝外疾病死亡,校正年齡與性別的影響後,皆以C型肝炎病毒慢性感染者(即C型肝炎病毒抗體陽性且核糖核酸陽性者)的風險最高;而C型肝炎病毒感染對於肝外疾病的影響,包含腦血管及腎臟疾病的死亡。結論:慢性C型肝炎病毒感染者有較高風險死於肝內及肝外疾病。 研究四、C型肝炎病毒感染與腦血管疾病死亡之風險 背景:C型肝炎病毒感染和腦血管疾病的關聯在過去的文獻仍未有定論。本研究目的在評估慢性C型肝炎病毒感染與腦血管疾病死亡的相關。方法:研究自1991至2008年追蹤年齡介於30-65歲的成年人共23,665名。在研究收案時即針對個案做問卷訪視,並收取血液檢體做病毒學及生化相關檢驗。研究個案的死亡情形,由連結死亡登記檔確認。 結果:經過382,011人年的追蹤,共有255名研究個案死於腦血管疾病。C型肝炎病毒抗體陰性者累積風險是1.0%,而C型肝炎病毒抗體陽性者累積風險則為2.7%,兩組間並達統計顯著差異。在校正其他腦血管疾病相關的危險因子之後,C肝抗體陽性者相對於陰性者死於腦血管疾病的風險為2.11倍 (95%信賴區間:1.42-3.14)。若以血清C肝抗體陰性者為參考組,針對C肝抗體陽性血清中偵測不到核醣核酸者、C肝抗體陽性血清病毒量低,以及C肝抗體陽性血清病毒量高者,校正後的風險對比值為1.43 (95%信賴區間:0.63-3.23), 2.29 (95%信賴區間:1.38-3.82)和2.81 (95%信賴區間:1.25-6.35),經過趨勢檢定之後,呈現劑量效應相關。而感染C型肝炎病毒的基因型別,則與腦血管疾病死亡無統計顯著相關。結論:C型肝炎病毒感染對於腦血管疾病有獨立於其他傳統危險因子的影響。 綜合本論文之研究顯示,C型肝炎病毒慢性感染者(C型肝炎血清抗體陽性且核糖核酸陽性),除了有較高的肝癌發生風險之外,也有較高的死於肝臟相關疾病,甚至其他肝外疾病的可能性;而這群慢性感染者,在社區中扮演重要的病毒傳播角色,可能有較高的機會將病毒傳染給他人。因此,利用核糖核酸的檢驗,找出慢性C型肝炎病毒感染者,予以適當的臨床處置,對於疾病的控制,甚至病毒感染的控制,有相當的重要性。 | zh_TW |
dc.description.abstract | This dissertation included four studies to investigate the prevalence of HCV infection and risk of hepatic/extrahepatic diseases associated with HCV infection.
Study 1: Geographical Variation and Determinants Associated with Anti-HCV Seroprevalence Background and Aims: Residents living in the same area may share similar likelihood to acquire infections. The risk factors for infection with hepatitis C virus (HCV) may be classified as individual and community risk factors. Individual risk factors of HCV infection have been extensively investigated whereas the community risk factors have been rarely evaluated. The aim of this epidemiological study was to explore the community risk factors, such as high HCV RNA positive rate and limited medical resources in a residential area, and the personal risk of HCV infection. Methods: This study enrolled 23,820 residents living in 155 villages in Taiwan to explore both individual and community risk factors for HCV infection. Antibodies against HCV (anti-HCV), HCV RNA and HCV genotype in serum samples were determined by enzyme immunoassay, polymerase chain reaction, and melting curve analysis, respectively. Results: The overall anti-HCV seroprevalence was 5.5%, HCV RNA was detectable in 68.1% of the seropositives of anti-HCV, and genotype 1 was the most prevalent genotype (54.6%). Personal risk factors for the seropositivity of anti-HCV included older ages, female gender, low educational level, and history of blood transfusion. Based on the multilevel analysis, persons living in villages with high HCV RNA-seropositive rates and limited health care resources had an increased seroprevalence of anti-HCV after adjustment for individual risk factors. The multivariate-adjusted odds ratio (95% confidence interval) was 3.74 (2.70-5.19) for high (versus low) seropositive rate of HCV RNA, and 1.90 (1.34-2.69) for limited (versus adequate) health care resource. Conclusions: This study suggests the community risk factors contribute significantly in the variation of anti-HCV seroprevalence. It implies both the adequacy of health care resources and the treatment of patients seropositive for HCV RNA will prevent individual residents from acquisition of HCV infection from the community. Study 2: Hepatitis C Seromarkers and Subsequent Risk of Hepatocellular Carcinoma Background and Aims: Hepatitis C virus (HCV) contributes to one-third of hepatocellular carcinoma cases worldwide. Long-term predictors for HCV-related hepatocellular carcinoma are essential for early intervention. Serum HCV RNA and alanine aminotransferase (ALT) levels and HCV genotype were assessed for their predictability of hepatocellular carcinoma risk. Methods: A prospective cohort of 925 participants positive for antibodies against HCV and aged 30-65 years were recruited and followed from 1991 to 2006. Serum HCV RNA and ALT levels and HCV genotypes at enrollment and during follow-up were examined. Newly-developed hepatocellular carcinoma was identified by health examination and computerized linkage with national cancer registration and death certification profiles. Multivariate-adjusted hazard ratios with 95% confidence intervals were estimated by Cox regression models. Results: There were 55 newly-developed hepatocellular carcinoma cases during 8,476 person-years of follow-up, giving an incidence rate of 648.9 per 100,000 person-years. The cumulative hepatocellular carcinoma risk increased from 1.1% for HCV RNA seronegatives, 6.4% for low HCV RNA levels, to 14.7% for high HCV RNA levels (p<0.001). The cumulative risk also increased with elevated serum ALT levels from 1.7% for persistently ≤15 U/L, 4.2% for ever >15 U/L but never >45 U/L, to 13.8% for ALT ever >45 U/L (p<0.001). HCV genotype 1 was associated with a higher cumulative hepatocellular carcinoma risk (12.6%) than HCV genotype non-1 (4.5%, p<0.001). Conclusions: Elevated serum levels of HCV RNA and ALT and HCV genotype 1 infection are independent risk predictors of hepatocellular carcinoma. These findings have strong implications for the management of chronic hepatitis C. Study 3: Hepatitis C Virus Infection Associated with Hepatic and Extrahepatic Mortality Background and Aims: Hepatitis C virus (HCV) infection is associated with hepatic and extrahepatic disease. However, it has rarely been examined the risk of all causes of death systematically after HCV infection, including those with persistent HCV infection. Methods: The R.E.V.E.A.L.-HCV cohort enrolled 23,820 adults aged 30-65 years old in community during 1991-1992. The seromarkers including HBsAg, anti-HCV, and serum HCV RNA were tested at study entry. The vital status was followed by computerized linkage with national death registration system from 1991-2008 via matching each participant’s name, identification number, and birthday and the specific causes of death were categorized according to ICD9. The mortality rate was calculated by the number of specific-cause of death divided by the person-years of follow-up. The Cox’s proportional hazards model was utilized to estimate the hazard ratios with 95% confidence intervals. Results: A total of 19,636 HBsAg seronegatives (18,541 anti-HCV seronegatives and 1,095 anti-HCV seropositives) included in this study. Among anti-HCV seropositives, 69.4% were positive for HCV RNA. There were 2394 deaths occurred in this cohort during an average of 16.2 year follow-up, giving an overall mortality rate of 753.4 per 100,000 person-years. The all cause mortality was 708.8 for anti-HCV seronegative, 741.0 for HCV RNA seronegatives, and 1879.8 per 100,000 person-years for HCV RNA seropositives. The liver-related mortalitywas 37.2, 82.3, 678.3 per 100,000 person-years for anti-HCV seronegatives, HCV RNA seronegatives, and HCV RNA seropositives, respectively. Participants with detectable HCV RNA had increased risk for extrahepatic diseases with trend (p<0.001), including deaths from cerebrovascular and renal diseases. Conclusion: Chronic hepatitis C patients had elevated risk for all-cause, liver-related, and extrahepatic diseases. Study 4: Chronic Hepatitis C Virus Infection and Cerebrovascular Disease Background and Aims: The association between hepatitis C virus (HCV) infection and cerebrovascular disease remains controversial. This study aimed to assess the risk of lethal cerebrovascular diseases associated with chronic HCV infection. Methods: In this community-based prospective cohort study, 23,665 residents (aged 30-65years) were enrolled in 1991-1992. They were personally interviewed using structuredquestionnaires and provided blood samples for various serological and biochemical tests at study entry. Serum HCV RNA level and HCV genotype were tested for participants seropositive for antibodies against HCV (anti-HCV). Deaths from cerebrovascular disease during follow-up were ascertained by computerized linkage with National Death Certification profiles from 1991 to 2008 (ICD-9: 430-438). Multivariate-adjusted hazard ratio (HR) with 95% confidence interval (CI) was estimated for each risk predictor. Results: There were 255 cerebrovascular deaths during 382,011 person-years of follow-up. The cumulative risk of cerebrovascular deaths were 1.0% and 2.7% for seronegatives and seropositives of anti-HCV, respectively (p<0.001). The HR (95% CI) of cerebrovascular death was 2.11 (1.42-3.14) for anti-HCV seropositives after adjustment for several conventional risk factors of cerebrovascular disease. Compared with participants seronegative for anti-HCV as the referent, the multivariate-adjusted HR (95% CI) was 1.43 (0.63-3.23), 2.29 (1.38-3.82) and 2.81 (1.25-6.35), respectively, for anti-HCV-seropositive participants with undetectable, low and high serum levels of HCV RNA (p<0.001 for trend). However, no significant association was found between HCV genotype and cerebrovascular death. Conclusions: Chronic HCV infection is an independent risk predictor of cerebrovascular deaths showing a biological gradient of cerebrovascular mortality with increasing serum HCV RNA level. In summary, HCV infection was prevalent and high HCV RNA positive rate in a community increased personal risk of HCV infection in that area. Moreover, anti-HCV seropositives with positive HCV RNA had elevated risks for both hepatic and extrahepatic diseases. Our results indicated that management of anti-HCV seropositives with HCV RNA viremia is important for HCV infection and HCV-related disease controls. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:48:56Z (GMT). No. of bitstreams: 1 ntu-99-D93842003-1.pdf: 699047 bytes, checksum: e6d4b8eb3b11f2ec21f6fb6988f2d106 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 中文摘要 I
ABSTRACT V CONTENTS X LIST OF TABLES XII LIST OF FIGUIRES XIV CHAPTER 1 Introduction 1 CHAPTER 2 Geographical Variation and Determinants Associated with Anti-HCV Seroprevalence 7 Introduction 7 Materials and Methods 8 Study area and participant enrollment 8 Community-level risk factors 9 Individual-level risk factors 9 Laboratory examinations 10 Statistical analysis 11 Results 12 Discussion 14 CHAPTER 3 Hepatitis C Seromarkers and Subsequent Risk of Hepatocellular Carcinoma 24 Introduction 24 Materials and Methods 25 Study cohort enrollment 25 Interview and blood collection 26 Laboratory examinations 26 Ascertainment of newly developed hepatocellular carcinoma 27 Statistical analysis 27 Results 28 Discussion 30 CHAPTER 4 Chronic Hepatitis C Virus Infection Associated with Hepatic and Extrahepatic Mortality 46 Introduction 46 Materials and Methods 47 Study cohort enrollment 47 Interview and blood collection 48 Laboratory examinations 48 Ascertainment of various disease deaths 49 Statistical analysis 49 Results 50 Discussion 52 CHAPTER 5 Chronic Hepatitis C Virus Infection and Cerebrovascular Disease 66 Introduction 66 Materials and Methods 67 Study cohort enrollment 67 Interview and blood collection 67 Laboratory examinations 68 Ascertainment of cerebrovascular disease death 68 Statistical analysis 69 Results 70 Discussion 71 CHAPTER 6 Conclusions and Perspectives 82 REFERENCES 85 | |
dc.language.iso | en | |
dc.title | 台灣C型肝炎病毒感染流行病學與健康風險評估 | zh_TW |
dc.title | Epidemiology and Health Risk Assessment of Hepatitis C Virus Infection in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 陳為堅(Wei J. Chen) | |
dc.contributor.oralexamcommittee | 陳培哲(Pei-Jer Chen),李文宗(Wen-Chung Lee),蕭朱杏(Chu-Hsing Kate Hsiao),楊懷壹(Hwai-I Yang) | |
dc.subject.keyword | C型肝炎病毒,C型肝炎病毒核糖核酸,C型肝炎病毒基因型,肝癌,肝外疾病,腦血管疾病, | zh_TW |
dc.subject.keyword | Hepatitis C Virus,HCV RNA,HCV Genotype,Hepatocellular Carcinoma,Extrahepatic Diseases,Cerebrovascular Disease, | en |
dc.relation.page | 104 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-03 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 682.66 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。